CTCAE results: Decrease in the incidence of ≥ grade 2 peripheral neuropathy in the intervention side ( p< .0001). The occurrence of ≥ grade 2 sensory neurotoxicity decreased from 76.1% to 21.4%, and that of motor neurotoxicity decreased from 57.1% to 26.2% Tofthagen C., Overcash J., & Kip K. (2012). Falls in persons with chemotherapy-induced peripheral neuropathy. Supportive Care in Cancer, 20( 3), 583–589. 10.1007/s00520-011-1127-7 [ PMC free article] [ PubMed] [ CrossRef] [ Google Scholar] Marks D. H., Qureshi A., & Friedman A. (2018). Evaluation of prevention interventions for taxane-induced dermatologic adverse events: A systematic review. JAMA Dermatology, 154( 12), 1465–1472. 10.1001/jamadermatol.2018.3465 [ PubMed] [ CrossRef] [ Google Scholar] Griffiths C., Kwon N., Beaumont J. L., & Paice J. A. (2018). Cold therapy to prevent paclitaxel-induced peripheral neuropathy. Supportive Care in Cancer, 26( 10), 3461–3469. 10.1007/s00520-018-4199-9 [ PubMed] [ CrossRef] [ Google Scholar] National Cancer Institute’s Common Toxicity Criteria, version 2.0, translated into Danish, including sensory neuropathy symptoms

The Impact of Peripheral Cooling on Chemotherapy-Induced

Although clinical exams for neuropathy and total neuropathy scores were performed, comparisons between intervention and control side not included in evaluation As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, Sato J., Mori M., Nihei S., Kumagai M., Takeuchi S., Kashiwaba M., & Kudo K. (2016). The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathy. Journal of Pharmaceutical Health Care and Sciences, 2, Article number: 33Occurrence of Patient Neurotoxicity Questionnaire grades D or E peripheral neuropathy reduced with intervention (hand: 2.8% vs. 41.7%, p< .001; foot: 2.8 vs. 36.1%, p< .001) Correlation between motor nerve amplitude preservation at 6 months and degree of skin cooling achieved, which demonstrated statistical significance ( p< .0005)

Frozen Socks - Etsy UK

Measurements at baseline, 2 weeks post treatment completion, and at first, fifth, ninth, and final weekly paclitaxel treatments Hanai A., Ishiguro H., Sozu T., Tsuda M., Yano I., Nakagawa T.,...Tsuboyama T. (2018). Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: Prospective self-controlled trial. Journal of the National Cancer Institute, 110( 2), 141–148. 10.1093/jnci/djx178 [ PMC free article] [ PubMed] [ CrossRef] [ Google Scholar] Pérez Fidalgo J. A., García Fabregat L., Cervantes A., Margulies A., Vidall C., & Roila F. (2012). Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Annals of Oncology, 23( Suppl 7), vii167–vii173. 10.1093/annonc/mds294 [ PubMed] [ CrossRef] [ Google Scholar] Symptoms assessed at baseline and before every cycle of paclitaxel administration during outpatient carePatient Neurotoxicity Questionnaire results: significantly lower grades of peripheral neuropathy in the intervention side ( p< .0001) Shah A., Hoffman E. M., Mauermann M. L., Loprinzi C. L., Windebank A. J., Klein C. J., & Staff N. P. (2018). Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. Journal of Neurology, Neurosurgery, and Psychiatry, 89( 6), 636–641. 10.1136/jnnp-2017-317215 [ PMC free article] [ PubMed] [ CrossRef] [ Google Scholar] Mols F., Beijers T., Vreugdenhil G., & van de Poll-Franse L. (2014). Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Supportive Care in Cancer, 22( 8), 2261–2269. 10.1007/s00520-014-2255-7 [ PubMed] [ CrossRef] [ Google Scholar]